IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12479797 B1

PDFFull Text
Date of Patent:
Nov. 25, 2025

Filed:

Apr. 29, 2022

Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors

Applicant:

Jubilant Epicore Llc, Yardley, PA (US);

Inventors:

Sridharan Rajagopal, Yeshwanthpur Bangalore, IN;

Mahanandeesha S. Hallur, Yeshwanthpur Bangalore, IN;

Purushottam Dewang, Yeshwanthpur Bangalore, IN;

Kannan Murugan, Yeshwanthpur Bangalore, IN;

Durga Prasanna Kumar C.H., Yeshwanthpur Bangalore, IN;

Pravin Iyer, Yeshwanthpur Bangalore, IN;

Chandrika Mulakala, Yeshwanthpur Bangalore, IN;

Dhanalakshmi Sivanandhan, Yeshwanthpur Bangalore, IN;

Sreekala Nair, Yeshwanthpur Bangalore, IN;

Mohd Zainuddin, Yeshwanthpur Bangalore, IN;

Subramanyam Janardhan Tantry, Yeshwanthpur Bangalore, IN;

Chandru Gajendran, Yeshwanthpur Bangalore, IN;

Sriram Rajagopal, Yeshwanthpur Bangalore, IN;

Assignee:

Jubilant Epicore LLC, Yardley, PA (US);

Attorney:

Seed Intellectual Property Law Group LLP

Primary Examiner:

Noble E Jarrell

Int. Cl.
CPC ...
A61P 35/00 (2006.01); C07C 235/56 (2006.01); C07C 237/20 (2006.01); C07C 259/08 (2006.01); C07D 205/04 (2006.01); C07D 205/12 (2006.01); C07D 209/44 (2006.01); C07D 211/26 (2006.01); C07D 217/18 (2006.01); C07D 231/12 (2006.01); C07D 233/64 (2006.01); C07D 239/26 (2006.01); C07D 249/04 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/06 (2006.01); C07D 417/12 (2006.01); C07D 487/04 (2006.01); C07D 495/04 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07D 205/12 (2013.01); A61P 35/00 (2018.01); C07C 235/56 (2013.01); C07C 237/20 (2013.01); C07C 259/08 (2013.01); C07D 205/04 (2013.01); C07D 209/44 (2013.01); C07D 211/26 (2013.01); C07D 217/18 (2013.01); C07D 231/12 (2013.01); C07D 233/64 (2013.01); C07D 239/26 (2013.01); C07D 249/04 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/06 (2013.01); C07D 417/12 (2013.01); C07D 487/04 (2013.01); C07D 495/04 (2013.01); A61K 45/06 (2013.01);
Abstract

The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.

Find Patent Forward Citations

Loading…